Avidity Biosciences (RNA) said Tuesday it has received orphan drug designation from Japan's Ministry of Health, Labor and Welfare for delpacibart etedesiran, or del-desiran, to potentially treat myotonic dystrophy type 1, a neuromuscular disease.
The investigational drug has also received breakthrough therapy, orphan drug and fast track designations by the US Food and Drug Administration, and orphan designation by the European Medicines Agency, Avidity said.
The company said it expects to complete enrollment in a phase 3 trial in the middle of this year and file marketing applications starting 2026 in the US, European Union and Japan.
Avidity shares were rising more than 2% in early trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。